

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING
REJECTION OVER A PENDING "REFERENCE" APPLICATION**

Docket Number (Optional)
31075/40037

In re Application of: Todd C. Zankel et al.

Application No.: 10/812,849-Conf. #3684

Filed: March 30, 2004

For: MEGALIN-BASED DELIVERY OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER
TISSUES

The owner*, RAPTOR PHARMACEUTICAL INC., of 100
percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of
any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any
patent granted on pending **reference** Application Number 11/202,566, filed on August 12, 2005,
as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said **reference** application may
be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application. The owner
hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it
and any patent granted on the **reference** application are commonly owned. This agreement runs with any patent granted on
the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant
application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent
granted on said **reference** application, "as the term of any patent granted on said **reference** application may be shortened by
any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such
patent: granted on the pending **reference** application: expires for failure to pay a maintenance fee, is held unenforceable, is
found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR
1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration
of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☒ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency,
etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on
information and belief are believed to be true; and further that these statements were made with the knowledge that willful false
statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United
States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 53,379

/Katherine L. Neville/ September 21, 2007
Signature Date

Katherine L. Neville
Typed or printed name

(312) 474-6300
Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing
system in accordance with § 1.6(a)(4).

Dated: September 21, 2007

Electronic Signature for Katherine L. Neville: /Katherine L. Neville 53,379/